Darlene Dobkowski, MA

For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.

Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.

Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior progression-free survival compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia.

Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Patients with relapsed/refractory diffuse large B-cell lymphoma treated with a novel combination of polatuzumab vetodin, rituximab and lenalidomide contributed to an improved overall response and complete response, with 82% remaining in remission at the study’s cutoff date.

Maintenance therapy with niraparib significantly improved progression-free survival in patients with BRCA-mutated ovarian cancer, according to results from three phase 3 trials.

Patients with cancer who live in states with lower Medicaid income eligibility limits had worse long-term survival outcomes compared with those with higher eligibility limits.

February 11, 2021 - A higher starting dose of lenvatinib — 18 mg per day — improved health-related quality of life and led to longer time to deterioration compared with a lower starting dose of lenvatinib — 14 mg per day — in patients with renal cell carcinoma.

January 28, 2021 - Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision.

January 15, 2021 - Findings from an analysis determined that stage 4 gastrointestinal stromal tumors were rare and led to hepatic metastases, although overall survival was up to 51% at 5 years.

December 11, 2020 - Patients with human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer who were treated with tesetaxel and a reduced dose of capecitabine experienced improvements in progression-free survival compared with those treated with the FDA-approved dose of capecitabine alone.

December 10, 2020 - Women with stage 1 to 3 breast cancer who adhered to a diabetes risk reduction diet had improved survival versus those who did not follow this specific diet.

December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.